Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon May 28, 2020 12:25pm

95 Views

Post# 31083253

RE:RE:RE:Incredible

For that 100 million they got some future tax losses plus that extra 100 million tax losses.

In Canada an arbitration usually lasts 3 months. I can't see anything tricky with this case but we're not privy to the disclosure. COVID May prolong this hearing but at the end of the day arbitration usually is very limited and will have both parties unsatisfied when complete. We should have sued them and took our chance in 9 years when it was settled.
I'm still not convinced this finished with arbitration. I'm still believing Bausch buys it back into there portfolio it's just at what price. It's so far a blockbuster in the U.S. so Cipher will want 15 million to settle.

Bullboard Posts

Nvidia reports record revenue in Q3